Skip to main content
SpringerLink
Log in

A cyclin D1-negative mantle cell lymphoma with an IGL-CCND2 translocation that relapsed with blastoid morphology and aggressive clinical behavior

  • Brief Report
  • Published:
Virchows Archiv Aims and scope Submit manuscript

Abstract

Mantle cell lymphoma (MCL) is a B cell neoplasm characterized by cyclin D1 overexpression; its prognosis is poor, especially when it exhibits a blastoid morphology. Cyclin D1-negative MCL is rare, and its pathogenesis and progression remain unclear. Herein, we describe a cyclin D1-negative, cyclin D2-positive MCL with a CCND2 and immunoglobulin lambda light chain (IGL) translocation. The patient was initially diagnosed with cyclin D1-negative MCL and achieved complete remission via combination chemotherapy and autologous stem cell transplantation. After relapsing, he was diagnosed with a blastoid variant of MCL that showed lymphoid cells with dispersed chromatin and more mitotic figures and higher p53 expression compared with the initial MCL. Despite salvage therapies, the disease became refractory, and the patient died 28 months after initiating chemotherapy. This case demonstrates that blastoid morphology in cyclin D1-negative MCL with IGL-CCND2 translocation indicates progression to a more aggressive neoplasm, similar to cyclin D1-positive MCL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  1. Sander B, Quintanilla-Martinez L, Ott G, Xerri L, Kuzu I, Chan JK, Swerdlow SH, Campo E (2015) Mantle cell lymphoma—a spectrum from indolent to aggressive disease Virchows Arch. doi: 10.1007/s00428-015-1840-6

  2. Gesk S, Klapper W, Martin-Subero JI, Nagel I, Harder L, Fu K, Bernd HW, Weisenburger DD, Parwaresch R, Siebert R (2006) A chromosomal translocation in cyclin D1-negative/cyclin D2-positive mantle cell lymphoma fuses the CCND2 gene to the IGK locus. Blood 108:1109–1110. doi:10.1182/blood-2006-01-0015

    Article  CAS  PubMed  Google Scholar 

  3. Quintanilla-Martinez L, Slotta-Huspenina J, Koch I, Klier M, Hsi ED, de Leval L, Klapper W, Gesk S, Siebert R, Fend F (2009) Differential diagnosis of cyclin D2+ mantle cell lymphoma based on fluorescence in situ hybridization and quantitative real-time-PCR. Haematologica 94:1595–1598. doi:10.3324/haematol.2009.010173

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Wlodarska I, Dierickx D, Vanhentenrijk V, Van Roosbroeck K, Pospisilova H, Minnei F, Verhoef G, Thomas J, Vandenberghe P, De Wolf-Peeters C (2008) Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas. Blood 111:5683–5690. doi:10.1182/blood-2007-10-118794

    Article  CAS  PubMed  Google Scholar 

  5. Shiller SM, Zieske A, Holmes H 3rd, Feldman AL, Law ME, Saad R (2011) CD5-positive, cyclinD1-negative mantle cell lymphoma with a translocation involving the CCND2 gene and the IGL locus. Cancer Genet 204:162–164. doi:10.1016/j.cancergencyto.2010.08.016

    Article  PubMed  Google Scholar 

  6. Salaverria I, Royo C, Carvajal-Cuenca A, Clot G, Navarro A, Valera A, Song JY, Woroniecka R, Rymkiewicz G, Klapper W, Hartmann EM, Sujobert P, Wlodarska I, Ferry JA, Gaulard P, Ott G, Rosenwald A, Lopez-Guillermo A, Quintanilla-Martinez L, Harris NL, Jaffe ES, Siebert R, Campo E, Bea S (2013) CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma. Blood 121:1394–1402. doi:10.1182/blood-2012-08-452284

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Jares P, Campo E (2008) Advances in the understanding of mantle cell lymphoma. Br J Haematol 142:149–165. doi:10.1111/j.1365-2141.2008.07124.x

    Article  CAS  PubMed  Google Scholar 

  8. Argatoff LH, Connors JM, Klasa RJ, Horsman DE, Gascoyne RD (1997) Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood 89:2067–2078

    CAS  PubMed  Google Scholar 

  9. Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, Pfreundschuh M, Reiser M, Metzner B, Einsele H, Peter N, Jung W, Wormann B, Ludwig WD, Duhrsen U, Eimermacher H, Wandt H, Hasford J, Hiddemann W, Unterhalt M, German Low Grade Lymphoma Study G, European Mantle Cell Lymphoma N (2008) A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111:558–565. doi:10.1182/blood-2007-06-095331

    Article  CAS  PubMed  Google Scholar 

  10. Kurita D, Miura K, Nakagawa M, Ohtake S, Sakagami M, Uchino Y, Takahashi H, Kiso S, Hojo A, Kodaira H, Yagi M, Hirabayashi Y, Kobayashi Y, Iriyama N, Kobayashi S, Hatta Y, Kura Y, Sugitani M, Takei M (2015) Dose-intensified CHOP with rituximab (R-Double-CHOP) followed by consolidation high-dose chemotherapies for patients with advanced diffuse large B-cell lymphoma. Int J Hematol 101:585–593. doi:10.1007/s12185-015-1780-6

    Article  CAS  PubMed  Google Scholar 

  11. Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, Asaka R, Hamanaka W, Ninomiya H, Uehara H, Lim Choi Y, Satoh Y, Okumura S, Nakagawa K, Mano H, Ishikawa Y (2012) RET, ROS1 and ALK fusions in lung cancer. Nat Med 18:378–381. doi:10.1038/nm.2658

    Article  CAS  PubMed  Google Scholar 

  12. Monni O, Oinonen R, Elonen E, Franssila K, Teerenhovi L, Joensuu H, Knuutila S (1998) Gain of 3q and deletion of 11q22 are frequent aberrations in mantle cell lymphoma. Genes Chromosomes Cancer 21:298–307

    Article  CAS  PubMed  Google Scholar 

  13. Hernandez L, Fest T, Cazorla M, Teruya-Feldstein J, Bosch F, Peinado MA, Piris MA, Montserrat E, Cardesa A, Jaffe ES, Campo E, Raffeld M (1996) p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood 87:3351–3359

    CAS  PubMed  Google Scholar 

  14. Slotta-Huspenina J, Koch I, de Leval L, Keller G, Klier M, Bink K, Kremer M, Raffeld M, Fend F, Quintanilla-Martinez L (2012) The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index. Haematologica 97:1422–1430. doi:10.3324/haematol.2011.055715

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Bernard M, Gressin R, Lefrere F, Drenou B, Branger B, Caulet-Maugendre S, Tass P, Brousse N, Valensi F, Milpied N, Voilat L, Sadoun A, Ghandour C, Hunault M, Leloup R, Mannone L, Hermine O, Lamy T (2001) Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype. Leukemia 15:1785–1791

    Article  CAS  PubMed  Google Scholar 

  16. Mozos A, Royo C, Hartmann E, De Jong D, Baro C, Valera A, Fu K, Weisenburger DD, Delabie J, Chuang SS, Jaffe ES, Ruiz-Marcellan C, Dave S, Rimsza L, Braziel R, Gascoyne RD, Sole F, Lopez-Guillermo A, Colomer D, Staudt LM, Rosenwald A, Ott G, Jares P, Campo E (2009) SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica 94:1555–1562. doi:10.3324/haematol.2009.010264

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Soldini D, Valera A, Sole C, Palomero J, Amador V, Martin-Subero JI, Ribera-Cortada I, Royo C, Salaverria I, Bea S, Gonzalvo E, Johannesson H, Herrera M, Colomo L, Martinez A, Campo E (2014) Assessment of SOX11 expression in routine lymphoma tissue sections: characterization of new monoclonal antibodies for diagnosis of mantle cell lymphoma. Am J Surg Pathol 38:86–93. doi:10.1097/PAS.0b013e3182a43996

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors thank Dr. Naoko Asano (Nagano Prefectural Suzaka Hospital) for performing the immunohistochemistry procedures and Mayumi Miura for the technical assistance.

Author information

Authors and Affiliations

  1. Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchi Kami-cho, Itabashi-ku, Tokyo, Japan

    Daisuke Kurita, Sumiko Kobayashi, Atsuko Hojo, Yoshihito Uchino, Masashi Sakagami, Shimon Ohtake, Hiromichi Takahashi, Katsuhiro Miura, Noriyoshi Iriyama, Yoshihiro Hatta & Masami Takei

  2. Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan

    Kengo Takeuchi

  3. Division of Hematology and Oncology, Kasukabe Municipal Hospital, Kasukabe, Japan

    Atsuko Hojo

  4. Department of Pathology, Nihon University School of Medicine, Itabashi-ku, Tokyo, Japan

    Masahiko Sugitani

  5. Department of Pathology, Kurume University School of Medicine, Kurume, Japan

    Daisuke Kurita, Hiroaki Miyoshi & Koichi Ohshima

Authors
  1. Daisuke Kurita
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kengo Takeuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sumiko Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Atsuko Hojo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yoshihito Uchino
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Masashi Sakagami
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shimon Ohtake
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hiromichi Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Katsuhiro Miura
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Noriyoshi Iriyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Masahiko Sugitani
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Hiroaki Miyoshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Yoshihiro Hatta
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Koichi Ohshima
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Masami Takei
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Daisuke Kurita or Yoshihiro Hatta.

Ethics declarations

Informed consent was obtained from the patient in accordance with the Declaration of Helsinki. Approval by a research ethics committee was not required because this was a case report of a single patient.

Funding

This study was not supported by any funding agencies.

Conflict of interest

The authors declare that they have no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kurita, D., Takeuchi, K., Kobayashi, S. et al. A cyclin D1-negative mantle cell lymphoma with an IGL-CCND2 translocation that relapsed with blastoid morphology and aggressive clinical behavior. Virchows Arch 469, 471–476 (2016). https://doi.org/10.1007/s00428-016-1995-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00428-016-1995-9

Keywords

Search

Navigation